Clinical data on potential treatments for the new coronavirus could help sustain a market bounce that has buoyed stocks after last month’s plunge, as investors look for signs that authorities may be able to stabilize the pandemic. Highly anticipated data for a Gilead Sciences Inc experimental antiviral drug are expected later this month. Analysts are also awaiting results in the near-term for products already approved for other conditions from companies such as Roche Holding and Regeneron Pharmaceuticals. …read more
Source:: Yahoo Finance
